The 'Ten Commandments' of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
- PMID: 36723982
- DOI: 10.1093/eurheartj/ehad018
The 'Ten Commandments' of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Conflict of interest statement
Conflict of Interest: S.R. has received fees for lectures and/or consultations from Abbott, Acceleron, Actelion, Aerovate, Altavant, AOP Orphan, AstraZeneca, Bayer, Boehringer Ingelheim, Edwards, Ferrer, Gossamer, Janssen, MSD, United Therapeutics, and Vifor; his institution has received research grants from Actelion, AstraZeneca, Bayer, and Janssen. M.D. has received institutional speaker, consultant, or steering committee fees from Acceleron, AOP, Bayer, Ferrer, Inari, Janssen, and MSD. Her institution has received research grants from Janssen. G.G. has received fees for lectures and/or consultation from Actelion, Bayer, ELPEN Pharmaceuticals, Galenica, GlaxoSmithKline, Janssen, MSD, Pfizer, Lilly, and United Therapeutics. M.M.H. has received fees for lectures and/or consultations from Acceleron, Actelion, AOP Health, Bayer, Ferrer, GossamerBio, Janssen, and MSD. G.K. has received fees for lectures and/or consultations from Actelion, AOP, Boehringer Ingelheim, Chiesi, Ferrer, Janssen, MSD, and Vitalaire. His institution has received research grants from Boehringer Ingelheim and Janssen. M.H. has received fees for lectures and/or consultations from Acceleron, Aerovate, Altavant, AOP Orphan, Bayer, Chiesi, Ferrer, Janssen, MSD, MorphogenIX, Shou Ti, and United Therapeutics; his research laboratory has received research grants from Acceleron, AOP Oprhan, Janssen, MSD, and Shou Ti.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical